| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6193027 | Journal of Thoracic Oncology | 2015 | 8 Pages |
Abstract
Cabazitaxel, a next-generation taxane, had inferior efficacy when compared with standard-dose topotecan in the treatment of relapsed SCLC. Topotecan remains a suboptimal therapy, and continued efforts to develop improved second-line treatments are warranted.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Tracey L. MD, Byoung Chul MD, PhD, Katalin MD, Juergen R. MD, Frances A. MD, Pablo MD, MSc, Rodryg MD, PhD, Konstantinos N. MD, PhD, Liji PhD, Mustapha MD, Martin MD,